NSE:VENUSREM (India)
Â
Shs Dematerialised
₹
1,581.6
+42.3 (+2.75%)
Jul 31
Business Description
Venus Remedies Ltd
ISIN : INE411B01019
Share Class Description:
NSE:VENUSREM: Shs DematerialisedTotal Employee Number:
1,298Compare
Compare
Traded in other countries / regions
526953.India IPO Date
2006-12-20Description
Venus Remedies Ltd is engaged in researching, discovering, developing, formulating, manufacturing, processing, refining, compounding, synthesising, extracting, importing, exporting, marketing, distributing, supplying, packaging, contract manufacturing, third-party manufacturing, and trading pharmaceutical, biopharmaceutical, biotechnology, healthcare, and allied products, including active pharmaceutical ingredients, formulations, biologics, biosimilars, vaccines, diagnostic products, medical devices, nutraceuticals, wellness products, veterinary products, cosmetics, and personal care products. The company operates in a single business segment, Pharmaceutical Formulation, engaged in the manufacturing and trading of medicines. It generates maximum revenue from India.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.97 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.07 | |||||
Interest Coverage | 4661 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 9.05 | |||||
Beneish M-Score | -2.76 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.9 | |||||
3-Year EBITDA Growth Rate | 31.5 | |||||
3-Year EPS without NRI Growth Rate | 54.6 | |||||
3-Year FCF Growth Rate | 60 | |||||
3-Year Book Growth Rate | 13 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.1 | |||||
9-Day RSI | 41.12 | |||||
14-Day RSI | 44.03 | |||||
3-1 Month Momentum % | 89.53 | |||||
6-1 Month Momentum % | 123.99 | |||||
12-1 Month Momentum % | 244.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.44 | |||||
Quick Ratio | 1.64 | |||||
Cash Ratio | 0.61 | |||||
Days Inventory | 103.03 | |||||
Days Sales Outstanding | 46.8 | |||||
Days Payable | 92.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward Dividend Yield % | 0.63 | |||||
Shareholder Yield % | 0.37 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 51.02 | |||||
Operating Margin % | 17.24 | |||||
Net Margin % | 14.32 | |||||
EBITDA Margin % | 21.93 | |||||
FCF Margin % | 14.55 | |||||
OCF Margin % | 19.2 | |||||
ROE % | 19.16 | |||||
ROA % | 14.91 | |||||
ROIC % | 20.77 | |||||
3-Year ROIIC % | 39.43 | |||||
ROC (Joel Greenblatt) % | 49.46 | |||||
ROCE % | 23.99 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 18.17 | |||||
Forward PE Ratio | 38.58 | |||||
PE Ratio without NRI | 18.17 | |||||
Shiller PE Ratio | 47.83 | |||||
Price-to-Owner-Earnings | 13.34 | |||||
PEG Ratio | 1.84 | |||||
PS Ratio | 2.6 | |||||
PB Ratio | 3.18 | |||||
Price-to-Tangible-Book | 3.7 | |||||
Price-to-Free-Cash-Flow | 17.87 | |||||
Price-to-Operating-Cash-Flow | 13.55 | |||||
EV-to-EBIT | 13.35 | |||||
EV-to-EBITDA | 11.38 | |||||
EV-to-Revenue | 2.49 | |||||
EV-to-FCF | 17.14 | |||||
Price-to-GF-Value | 3.08 | |||||
Price-to-Projected-FCF | 1.41 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.41 | |||||
Price-to-Graham-Number | 1.84 | |||||
| Price-to-Net-Current-Asset-Value | 10.28 | |||||
Earnings Yield (Greenblatt) % | 7.49 | |||||
FCF Yield % | 5.59 | |||||
Forward Rate of Return (Yacktman) % | 13.2 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Venus Remedies Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 8,112.7 | ||
| EPS (TTM) (₹) | 86.91 | ||
| Beta | 0.6082 | ||
| 3-Year Sharpe Ratio | 1.23 | ||
| 3-Year Sortino Ratio | 3.66 | ||
| Volatility % | 83.78 | ||
| 14-Day RSI | 44.03 | ||
| 14-Day ATR (₹) | 102.883228 | ||
| 20-Day SMA (₹) | 1695.545 | ||
| 12-1 Month Momentum % | 244.58 | ||
| 52-Week Range (₹) | 424 - 2044.3 | ||
| Shares Outstanding (Mil) | 13.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Venus Remedies Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Venus Remedies Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 10.000000 Cash Dividend | 2026-08-07 | In 4 days |
Show
Entries
Venus Remedies Ltd Frequently Asked Questions
What is Venus Remedies Ltd(NSE:VENUSREM)'s stock price today?
The current price of NSE:VENUSREM is ₹1581.60. The 52 week high of NSE:VENUSREM is ₹2044.30 and 52 week low is ₹424.00.
When is next earnings date of Venus Remedies Ltd(NSE:VENUSREM)?
The next earnings date of Venus Remedies Ltd(NSE:VENUSREM) is .
Does Venus Remedies Ltd(NSE:VENUSREM) pay dividends? If so, how much?
Venus Remedies Ltd(NSE:VENUSREM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Venus Remedies Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers